WACKER opened the mRNA Competence Center in June of 2024 in Halle an der Saale, Germany. Representing an investment of over €100 million, the next-generation facility enables the large-scale production of active ingredients based on messenger ribonucleic acid (mRNA). The building spans a total floor area of 79,653 sf and accommodates four new lines supported by advanced infrastructure, including 17,222 sf of glass-enclosed cleanroom space for bioprocessing under controlled conditions.
Exyte provided engineering, procurement, construction, and quality control (EPCQ) services for the development, which can supply more than 200 million vaccine doses each year. Some of the plant’s capacity will be made available to the German government as part of its pandemic-preparedness program. The mRNA Competence Center was delivered in just two years.
| Organization | Project Role |
|---|---|
|
Exyte
|
Integrated EPCQ Provider
|
